Rofecoxib inhibits heterotopic ossification after total hip arthroplasty.

Abstract

INTRODUCTION:

Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent heterotopic ossification but gastrointestinal complaints are frequently. Selective cyclooxygenase-2 (COX-2) inhibiting NSAID produce less gastrointestinal side effects.

PATIENTS AND METHODS:

A prospective two-stage study design for phase 2 clinical trials with 42 patients was used to determine if rofecoxib (a COX-2 inhibitor) 50 mg oral for 7 days prevents heterotopic ossification. A cemented primary THA was inserted for osteoarthroses. After 6 months heterotopic bone formation was assessed on AP radiographs using the Brooker classification.

RESULTS:

No heterotopic ossification was found in 81% of the patients, 19% of the patients had Brooker grade 1 ossification.

CONCLUSION:

Using a two-stage study design for phase 2 clinical trials, a 7-day treatment of a COX-2 inhibitor (rofecoxib) prevents effectively the formation of heterotopic ossification after cemented primary total hip arthroplasty.

• Authors: Huub J L van der Heide, Rinco C T Koorevaar, J Albert M Lemmens, Albert van Kampen, B Willem Schreurs
• Journal: Archives of orthopaedic and trauma surgery (Arch Orthop Trauma Surg) Vol. 127 Issue 7 Pg. 557-61 (Sep 2007) ISSN: 0936-8051 [Print] Germany
• PMID: 17106714 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Cyclooxygenase 2 Inhibitors
• Lactones
• Sulfones
• rofecoxib

Topics

• Adult
• Aged
• Aged, 80 and over
• Arthroplasty, Replacement, Hip (adverse effects)
• Cyclooxygenase 2 Inhibitors (therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Lactones (therapeutic use)
• Male
• Middle Aged
• Ossification, Heterotopic (prevention & control)
• Prospective Studies
• Research Design
• Sulfones (therapeutic use)